FIELD: pharmaceuticals.
SUBSTANCE: invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1. The invention also relates to a pharmaceutical composition containing an anti-LILRB1 antibody or antigen-binding fragment thereof for the treatment or prevention of cancer characterized by MHC class I overexpression, a nucleic acid molecule encoding an anti-LILRB1 antibody or an antigen-binding fragment thereof, a recombinant expression vector, a recombinant cell producing an anti-LILRB1 antibody or antigen-binding fragment thereof, and a method for producing an anti-LILRB1 antibody or antigen-binding fragment thereof.
EFFECT: obtaining anti-lilrb1 antibody and its use.
9 cl, 12 dwg, 28 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| ANTI-HUMAN ANGIOPOIETIN-LIKE 4 PROTEIN ANTIBODIES | 2010 |
|
RU2580045C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2023 |
|
RU2802944C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
